This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In this issue of Neurology®, Rosas et al.1 present a phase II trial of creatine in Huntington disease (HD). This study is remarkable not only for the demonstration of safety and tolerability but also because the study design establishes the feasibility of clinical trials among premanifest HD individuals. Notably, the trial is undertaken in the disease prodrome, when the participants are clinically unaffected by HD, rather than in established disease. Furthermore, not all participants knew their mutation carrier status. The trial design defines methods to preserve confidentiality and overcomes the difficulty of studying HD at its earliest phase by avoiding the requirement to include only the genetically tested. The success of this study demonstrates that sufficient discriminant power can be obtained without the exclusion of genetically untested at-risk individuals.
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 850
- © 2014 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.